Details of the Drug

General Information of Drug (ID: DMXIQYS)

Drug Name
Iodipamide
Synonyms
Adipiodon; Adipiodona; Adipiodone; Adipiodonum; Bilignost; Bilignostum; Biligrafin; Cholografin; Cholospect; IDB; Transbilix; Iodipamic acid; Iodipamide [USAN]; Adipiodona [INN-Spanish]; Adipiodonum [INN-Latin]; Iodipamide (USP); Adipiodone (JAN/INN); N,N''-Adipoyl-bis(3-amino-2,4,6-triiodbenzoesaeure); 3,3'(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-Adipoyldiiminobis(2,4,6-triiodobenzoic Acid); 3,3'-[(1,6-DIOXOHEXANE-1,6-DIYL)DIIMINO]BIS(2,4,6-TRIIODOBENZOIC ACID); 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID; 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
Indication
Disease Entry ICD 11 Status REF
Gallbladder disease DC11.3 Approved [1], [2], [3]
Therapeutic Class
Contrast Media
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 1139.8
Topological Polar Surface Area (xlogp) 5.5
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Metabolism
The drug is metabolized via the hepatic [4]
Chemical Identifiers
Formula
C20H14I6N2O6
IUPAC Name
3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
Canonical SMILES
C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I
InChI
InChI=1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)
InChIKey
FFINMCNLQNTKLU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3739
ChEBI ID
CHEBI:31176
CAS Number
606-17-7
DrugBank ID
DB04711
TTD ID
D07OIX

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serum albumin (ALB) TTFNGC9 ALBU_HUMAN Binder [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Gallbladder disease
ICD Disease Classification DC11.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serum albumin (ALB) DTT ALB 7.92E-01 -0.07 -0.44
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Iodipamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Iodipamide caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [16]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Iodipamide and Inotersen. Amyloidosis [5D00] [17]
177Lu-DOTATATE DMT8GVU Major Increased risk of nephrotoxicity by the combination of Iodipamide and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [17]
Givosiran DM5PFIJ Major Increased risk of nephrotoxicity by the combination of Iodipamide and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [17]
Moxetumomab pasudotox DMN63DZ Major Increased risk of nephrotoxicity by the combination of Iodipamide and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [17]
Gallium nitrate DMF9O6B Major Increased risk of nephrotoxicity by the combination of Iodipamide and Gallium nitrate. Mineral excesses [5B91] [18]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Iodipamide and Temsirolimus. Renal cell carcinoma [2C90] [18]
Telavancin DM58VQX Major Increased risk of nephrotoxicity by the combination of Iodipamide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [18]
Plazomicin DMKMBES Major Increased risk of nephrotoxicity by the combination of Iodipamide and Plazomicin. Urinary tract infection [GC08] [17]
⏷ Show the Full List of 9 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7400).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009321.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
6 Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
7 Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
8 Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
9 Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
10 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
13 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
14 ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
15 Clinical pipeline report, company report or official report of Ablynx.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74. [PMID: 20502171]
18 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]